Actively Recruiting
Study of Vitamin B3 with Tislelizumab, Gemcitabine, and Cisplatin for Bladder Cancer Patients Evaluating Safety and Effects Following Antibiotic Use
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2026-06-30
12
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying bladder cancer patients who receive treatments that activate their immune system to fight tumors. This study aims to determine if taking Vitamin B3 as a dietary supplement can prevent antibiotics, which kill bacteria, from reducing the effectiveness of these immune-activating treatments. The trial focuses on patients with urothelial carcinoma who have had recent infections requiring bactericidal antibiotics. Participants will receive a combination of drugs including tislelizumab, gemcitabine, and cisplatin in 21-day cycles for up to six cycles. Vitamin B3 supplementation at two predefined doses will be taken daily alongside these treatments. After the initial chemoimmunotherapy, maintenance therapy with tislelizumab continues every three weeks for up to two years or until treatment is stopped. During the trial, participants will be closely monitored with assessments to determine the dose-limiting toxicity of Vitamin B3 over the first 28 days. Researchers will also evaluate safety, adverse events, and the pathological response of tumors over 24 months. Participants will have regular visits for treatment administration and monitoring, with the total study participation lasting up to two years.
CONDITIONS
Brief Title
Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients
Research Team
D
Daqin Wu, Ph.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here